Nascent Biotech Stock Today
| NBIO Stock | USD 0.01 0 16.67% |
PerformanceGood
| Odds Of DistressBelow Average
|
Nascent Biotech is selling at 0.0075 as of the 1st of March 2025; that is 16.67 percent decrease since the beginning of the trading day. The stock's open price was 0.009. Nascent Biotech has about a 38 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 30th of January 2025 and ending today, the 1st of March 2025. Click here to learn more.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. The company has 119.56 M outstanding shares. More on Nascent Biotech
Moving together with Nascent OTC Stock
| 0.66 | NVO | Novo Nordisk AS | PairCorr |
| 0.65 | NONOF | Novo Nordisk AS | PairCorr |
| 0.8 | CSLLY | CSL | PairCorr |
| 0.73 | REGN | Regeneron Pharmaceuticals | PairCorr |
Moving against Nascent OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nascent OTC Stock Highlights
| Chairman | Mark Glassy |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Nascent Biotech [NBIO] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nascent Biotech's market, we take the total number of its shares issued and multiply it by Nascent Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nascent Biotech conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 119.56 M outstanding shares.
Nascent Biotech currently holds about 145.57 K in cash with 413.48 K of positive cash flow from operations.
Check Nascent Biotech Probability Of Bankruptcy
Ownership AllocationNascent Biotech maintains a total of 119.56 Million outstanding shares. Nascent Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nascent Ownership Details
Nascent Biotech Risk Profiles
| Mean Deviation | 25.19 | |||
| Semi Deviation | 13.94 | |||
| Standard Deviation | 82.36 | |||
| Variance | 6783.01 |
Nascent Stock Against Markets
Picking the right benchmark for Nascent Biotech otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nascent Biotech otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nascent Biotech is critical whether you are bullish or bearish towards Nascent Biotech at a given time. Please also check how Nascent Biotech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Nascent Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.